Agrin gene therapy

Agrin gene therapy has been studied in 1 paper since 2024: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Mar 9, 2024: “Deficiency of skeletal muscle Agrin contributes to the pathogenesis of age-related sarcopenia in mice”.

Intervention

1 paper studies it3 findingsUpdated

See all 1 papers on agrin gene therapy

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Funders: National Natural Science Foundation of China and 1 more
  • Animals1

What did studies of agrin gene therapy find?

3

Studies of agrin gene therapy measured 3 outcomes: DAG1, hippo–YAP signaling and muscle capacity.

DAG1

upin mice1

1 study
  1. Agrin gene therapy increases DAG1 in mice.

    “concurrent upregulation of dystroglycan expression”

    Animalsskeletal muscle

    Deficiency of skeletal muscle Agrin contributes to the pathogenesis of age-related sarcopenia in mice

    Cell death & disease

More on DAG1

Hippo–YAP signaling

upin mice1

1 study
  1. Agrin gene therapy activates hippo–YAP signaling in mice.

    “Agrin-mediated improvement in muscle function occurs through the stimulation of Yap signaling”

    Animalsskeletal muscle

    Deficiency of skeletal muscle Agrin contributes to the pathogenesis of age-related sarcopenia in mice

    Cell death & disease

More on Hippo–YAP signaling

Muscle capacity

upin mice1

1 study
  1. Agrin gene therapy improves muscle capacity in mice (adenovirus-mediated gene transfer).

    “elevation of a miniaturized form of Agrin in skeletal muscle through adenovirus-mediated gene transfer induces enhanced muscle capacity in aged mice”

    Animalsadenovirus-mediated gene transferminiaturized formskeletal muscle

    Deficiency of skeletal muscle Agrin contributes to the pathogenesis of age-related sarcopenia in mice

    Cell death & disease

Latest